Polymer nanoparticulate drug delivery and combination cancer therapy

Future Oncology

Volumn 8, Issue 11, 2012, Pages 1471-1480

  Cao, Pengxiao ^a   Bae, Younsoo ^a  

^a University of Kentucky   (United States)

Author keywords

biomaterials; cancer; chemotherapy; combination therapy; drug delivery; drug formulation; gene therapy; nanotechnology; pharmaceutical science; polymer nanoparticles

Indexed keywords

AMINOSALICYLIC ACID; BEVACIZUMAB; CAMPTOTHECIN; CERAMIDE; CETUXIMAB; CISPLATIN; CIXUTUMUMAB; COMBRETASTATIN; DASATINIB; DOXORUBICIN; DRUG CARRIER; ERLOTINIB; ETOPOSIDE; FIRTECAN; FLUOROURACIL; GIMERACIL; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; IMATINIB; LAPATINIB; MACROGOL; NANOPARTICLE; OTERACIL; PACLITAXEL; POLYMER; RAMUCIRUMAB; REGORAFENIB; SELUMETINIB; SORAFENIB; TANESPIMYCIN; UNINDEXED DRUG;

CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER GENE THERAPY; CANCER INHIBITION; CANCER RESEARCH; CONTROLLED DRUG RELEASE; CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG SOLUBILITY; ENZYME ACTIVITY; HEAT; HISTIOCYTE; HUMAN; KUPFFER CELL; LIGHT; MACROPHAGE; MEMBRANE PERMEABILITY; MICELLE; MOLECULARLY TARGETED THERAPY; MULTIDRUG RESISTANCE; NANOTECHNOLOGY; NONHUMAN; OXIDATIVE STRESS; PARTICLE SIZE; PH; PRIORITY JOURNAL; REVIEW; ULTRASOUND;

ANIMALS; ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; DRUG CARRIERS; DRUG COMBINATIONS; DRUG DELIVERY SYSTEMS; GENETIC THERAPY; HUMANS; MOLECULAR TARGETED THERAPY; NANOPARTICLES; NEOPLASMS; POLYMERS; SIGNAL TRANSDUCTION;

EID: 84869168479     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.12.139     Document Type: Review

References (76)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J. Clin. 62(1), 10-29 (2012).
2. Chute JP, Chen T, Feigal E, Simon R, Johnson BE. Twenty years of Phase III trials for patients with extensive-stage small-cell lung cancer: Perceptible progress. J. Clin. Oncol. 17(6), 1794-1801 (1999). (Pubitemid 29269249)
3. Gardner GJ, Jewell EL. Current and future directions of clinical trials for ovarian cancer. Cancer Control 18(1), 44-51 (2011).
4. Graham JS, Cassidy J. Adjuvant therapy in colon cancer. Expert Rev. Anticancer Ther. 12(1), 99-109 (2012).
5. van Meerbeeck JP, Fennell DA, De Ruysscher DK. Small-cell lung cancer. Lancet 378(9804), 1741-1755 (2011).
6. Lee JH, Nan A. Combination drug delivery approaches in metastatic breast cancer. J. Drug Deliv. doi:10.1155/2012/915375 (2012) (Epub ahead of print).
7. Baselga J, Bradbury I, Eidtmann H et al. Lapatinib with trastuzumab for HER2- positive early breast cancer (NeoALTTO): A randomised, open-label, multicentre, Phase 3 trial. Lancet 379(9816), 633-640 (2012).
8. Bliesath J, Huser N, Omori M et al. Combined inhibition of EGFR and CK2 augments the attenuation of PI3K-Akt-mTOR signaling and the killing of cancer cells. Cancer Lett. 322(1), 113-118 (2012).
9. Holt SV, Logie A, Odedra R et al. The MEK1/2 inhibitor, selumetinib (AZD6244; ARRY-142886), enhances anti-tumour efficacy when combined with conventional chemotherapeutic agents in human tumour xenograft models. Br. J. Cancer 106(5), 858-866 (2012).
10. Jaglowski S, Jones JA. Choosing first-line therapy for chronic lymphocytic leukemia. Expert Rev. Anticancer Ther. 11(9), 1379-1390 (2011).
11. Kinsella P, Clynes M, Amberger-Murphy V. Imatinib and docetaxel in combination can effectively inhibit glioma invasion in an in vitro 3D invasion assay. J. Neurooncol. 101(2), 189-198 (2011).
12. Larbouret C, Gaborit N, Chardes T et al. In pancreatic carcinoma, dual EGFR/HER2 targeting with cetuximab/trastuzumab is more effective than treatment with trastuzumab/erlotinib or lapatinib alone: Implication of receptors' down-regulation and dimers' disruption. Neoplasia 14(2), 121-130 (2012).
13. Pichot CS, Hartig SM, Xia L et al. Dasatinib synergizes with doxorubicin to block growth, migration, and invasion of breast cancer cells. Br. J. Cancer 101(1), 38-47 (2009).
14. Von Minckwitz G, Loibl S, Untch M. What is the current standard of care for anti-HER2 neoadjuvant therapy in breast cancer? Oncology 26(1), 20-26 (2012).
15. Wu CL, Ping SY, Yu CP, Yu DS. Tyrosine kinase receptor inhibitor-targeted combined chemotherapy for metastatic bladder cancer. Kaohsiung J. Med. Sci. 28(4), 194-203 (2012).
16. Duncan R. Polymer conjugates for drug targeting. From inspired to inspiration! J. Drug Target 14(6), 333-335 (2006). (Pubitemid 44203513)
17. Haley B, Frenkel E. Nanoparticles for drug delivery in cancer treatment. Urol. Oncol. 26(1), 57-64 (2008).
18. Malam Y, Lim EJ, Seifalian AM. Current trends in the application of nanoparticles in drug delivery. Curr. Med. Chem. 18(7), 1067-1078 (2011).
19. McNeil SE. Unique benefits of nanotechnology to drug delivery and diagnostics. Methods Mol. Biol. 697, 3-8 (2011).
20. Wang AZ, Langer R, Farokhzad OC. Nanoparticle delivery of cancer drugs. Annu. Rev. Med. 63, 185-198 (2012).
21. Yang H, Liu C, Yang DF, Zhang HS, Xi ZG. Comparative study of cytotoxicity, oxidative stress and genotoxicity induced by four typical nanomaterials: The role of particle size, shape and composition. J. Appl. Toxicol. 29(1), 69-78 (2009).
22. Jin H, Heller DA, Sharma R, Strano MS. Size-dependent cellular uptake and expulsion of single-walled carbon nanotubes: Single particle tracking and a generic uptake model for nanoparticles. ACS Nano 3(1), 149-158 (2009).
23. He CB, Hu YP, Yin LC, Tang C, Yin CH. Effects of particle size and surface charge on cellular uptake and biodistribution of polymeric nanoparticles. Biomaterials 31(13), 3657-3666 (2010).
24. Cho EC, Au L, Zhang Q, Xia YN. The effects of size, shape, and surface functional group of gold nanostructures on their adsorption and internalization by cells. Small 6(4), 517-522 (2010).
25. Torchilin V. Tumor delivery of macromolecular drugs based on the EPR effect. Adv. Drug Deliv. Rev. 63(3), 131-135 (2011).
26. Zhang L, Gu FX, Chan JM, Wang AZ, Langer RS, Farokhzad OC. Nanoparticles in medicine: Therapeutic applications and developments. Clin. Pharmacol. Ther. 83(5), 761-769 (2008). (Pubitemid 351556021)
27. Torchilin VP. Passive and active drug targeting: drug delivery to tumors as an example. Handb. Exp. Pharmacol. (197), 3-53 (2010).
28. Bae Y, Jang WD, Nishiyama N, Fukushima S, Kataoka K. Multifunctional polymeric micelles with folate-mediated cancer cell targeting and pH-triggered drug releasing properties for active intracellular drug delivery. Mol. Biosyst. 1(3), 242-250 (2005). (Pubitemid 41442434)
29. West KR, Otto S. Reversible covalent chemistry in drug delivery. Curr. Drug Discov. Technol. 2(3), 123-160 (2005). (Pubitemid 41242960)
30. Fleige E, Quadir MA, Haag R. Stimuli-responsive polymeric nanocarriers for the controlled transport of active compounds: Concepts and applications. Adv. Drug Deliv. Rev. 64(9), 866-884 (2012).
31. Radjenovic B, Radmilovic-Radjenovic M. Top down nano technologies in surface modification of materials. Cent. Eur. J. Phys. 9(2), 265-275 (2011).
32. Pattekari P, Zheng Z, Zhang X, Levchenko T, Torchilin V, Lvov Y. Top-down and bottom-up approaches in production of aqueous nanocolloids of low solubility drug paclitaxel. Phys. Chem. Chem. Phys. 13(19), 9014-9019 (2011).
33. Shimomura M, Sawadaishi T. Bottom-up strategy of materials fabrication: A new trend in nanotechnology of soft materials. Curr. Opin. Coll. In. 6(1), 11-16 (2001). (Pubitemid 32233060)
34. Tu RS, Tirrell M. Bottom-up design of biomimetic assemblies. Adv. Drug Deliver. Rev. 56(11), 1537-1563 (2004). (Pubitemid 39177688)
35. Lee SW, Chang WJ, Bashir R, Koo YM. 'Bottom-up' approach for implementing nano/microstructure using biological and chemical interactions. Biotechnol. Bioproc. E. 12(3), 185-199 (2007). (Pubitemid 47045742)
36. Gaspar R, Duncan R. Polymeric carriers: Preclinical safety and the regulatory implications for design and development of polymer therapeutics. Adv. Drug Deliv. Rev. 61(13), 1220-1231 (2009).
37. Kim S, Kim JH, Jeon O, Kwon IC, Park K. Engineered polymers for advanced drug delivery. Eur. J. Pharm. Biopharm. 71(3), 420-430 (2009).
38. Chou TC. Drug combination studies and their synergy quantification using the chou-talalay method. Cancer Res. 70(2), 440-446 (2010).
39. Hu CM, Aryal S, Zhang L. Nanoparticle-assisted combination therapies for effective cancer treatment. Ther. Deliv. 1(2), 323-334 (2010).
40. Ganta S, Devalapally H, Shahiwala A, Amiji M. A review of stimuli-responsive nanocarriers for drug and gene delivery. J. Control Release 126(3), 187-204 (2008).
41. Brewer E, Coleman J, Lowman A. Emerging technologies of polymeric nanoparticles in cancer drug delivery. J. Nanomater. doi:10.1155/2011/408675 (2011) (Epub ahead of print).
42. Kim DW, Kim SY, Kim HK et al. Multicenter Phase II trial of Genexol-PM, a novel Cremophor-free, polymeric micelle formulation of paclitaxel, with cisplatin in patients with advanced non-small-cell lung cancer. Ann. Oncol. 18(12), 2009-2014 (2007).
43. Lee KS, Chung HC, Im SA et al. Multicenter Phase II trial of Genexol-PM, a Cremophor-free, polymeric micelle formulation of paclitaxel, in patients with metastatic breast cancer. Breast Cancer Res. Treat. 108(2), 241-250 (2008). (Pubitemid 351311357)
44. Nakajima TE, Yasunaga M, Kano Y et al. Synergistic antitumor activity of the novel SN-38-incorporating polymeric micelles, NK012, combined with 5-fluorouracil in a mouse model of colorectal cancer, as compared with that of irinotecan plus 5-fluorouracil. Int. J. Cancer 122(9), 2148-2153 (2008). (Pubitemid 351441208)
45. Nagano T, Yasunaga M, Goto K et al. Antitumor activity of NK012 combined with cisplatin against small cell lung cancer and intestinal mucosal changes in tumor-bearing mouse after treatment. Clin. Cancer Res. 15(13), 4348-4355 (2009).
46. Nagano T, Yasunaga M, Goto K et al. Synergistic antitumor activity of the SN-38-incorporating polymeric micelles NK012 with S-1 in a mouse model of non-small cell lung cancer. Int. J. Cancer 127(11), 2699-2706 (2010).
47. Na HS, Lim YK, Jeong YI et al. Combination antitumor effects of micelle-loaded anticancer drugs in a CT-26 murine colorectal carcinoma model. Int. J. Pharm. 383(1-2), 192-200 (2010).
48. Wang H, Zhao Y, Wu Y et al. Enhanced anti-tumor efficacy by co-delivery of doxorubicin and paclitaxel with amphiphilic methoxy PEG-PLGA copolymer nanoparticles. Biomaterials 32(32), 8281-8290 (2011).
49. Wang Z, Chui WK, Ho PC. Nanoparticulate delivery system targeted to tumor neovasculature for combined anticancer and antiangiogenesis therapy. Pharm. Res. 28(3), 585-596 (2011).
50. Shin HC, Alani AW, Cho H, Bae Y, Kolesar JM, Kwon GS. A 3-in-1 polymeric micelle nanocontainer for poorly water-soluble drugs. Mol. Pharm. 8(4), 1257-1265 (2011).
51. Cho H, Kwon GS. Polymeric micelles for neoadjuvant cancer therapy and tumor-primed optical imaging. ACS Nano 5(11), 8721-8729 (2011).
52. Bae Y, Alani AW, Rockich NC, Lai TS, Kwon GS. Mixed pH-sensitive polymeric micelles for combination drug delivery. Pharm. Res. 27(11), 2421-2432 (2010).
53. Bae Y, Diezi TA, Zhao A, Kwon GS. Mixed polymeric micelles for combination cancer chemotherapy through the concurrent delivery of multiple chemotherapeutic agents. J. Control. Release 122(3), 324-330 (2007). (Pubitemid 47404677)
54. Aryal S, Hu CM, Zhang L. Polymeric nanoparticles with precise ratiometric control over drug loading for combination therapy. Mol. Pharm. 8(4), 1401-1407 (2011).
55. Cervello M, McCubrey JA, Cusimano A, Lampiasi N, Azzolina A, Montalto G. Targeted therapy for hepatocellular carcinoma: novel agents on the horizon. Oncotarget 3(3), 236-260 (2012).
56. Kenmotsu H, Yasunaga M, Goto K et al. The antitumor activity of NK012, an SN-38- incorporating micelle, in combination with bevacizumab against lung cancer xenografts. Cancer 116(19), 4597-4604 (2010).
57. Sun TM, Du JZ, Yan LF, Mao HQ, Wang J. Self-assembled biodegradable micellar nanoparticles of amphiphilic and cationic block copolymer for siRNA delivery. Biomaterials 29(32), 4348-4355 (2008).
58. Huang HY, Kuo WT, Chou MJ, Huang YY. Co-delivery of anti-vascular endothelial growth factor siRNA and doxorubicin by multifunctional polymeric micelle for tumor growth suppression. J. Biomed. Mater. Res. A. 97(3), 330-338 (2011).
59. Benoit DS, Henry SM, Shubin AD, Hoffman AS, Stayton PS. pH-responsive polymeric sirna carriers sensitize multidrug resistant ovarian cancer cells to doxorubicin via knockdown of polo-like kinase 1. Mol. Pharm. 7(2), 442-455 (2010).
60. Zhu C, Jung S, Luo S et al. Co-delivery of siRNA and paclitaxel into cancer cells by biodegradable cationic micelles based on PDMAEMA-PCL-PDMAEMA triblock copolymers. Biomaterials 31(8), 2408-2416 (2010).
61. Sun TM, Du JZ, Yao YD et al. Simultaneous delivery of siRNA and paclitaxel via a 'two-in-one' micelleplex promotes synergistic tumor suppression. ACS Nano 5(2), 1483-1494 (2011).
62. Guo PX. The emerging field of RNA nanotechnology. Nat. Nanotechnol. 5(12), 833-842 (2010).
63. Shu D, Shu Y, Haque F, Abdelmawla S, Guo PX. Thermodynamically stable RNA three-way junction for constructing multifunctional nanoparticles for delivery of therapeutics. Nat. Nanotechnol. 6(10), 658-667 (2011).
64. Afonin KA, Bindewald E, Yaghoubian AJ et al. In vitro assembly of cubic RNA-based scaffolds designed in silico. Nat. Nanotechnol. 5(9), 676-682 (2010).
65. Dicko A, Mayer LD, Tardi PG. Use of nanoscale delivery systems to maintain synergistic drug ratios in vivo. Expert Opin. Drug Deliv. 7(12), 1329-1341 (2010).
66. Hu CM, Zhang L. Nanoparticle-based combination therapy toward overcoming drug resistance in cancer. Biochem. Pharmacol. 83(8), 1104-1111 (2012).
67. Yang T, Wang Y, Li Z et al. Targeted delivery of a combination therapy consisting of combretastatin A4 and low-dose doxorubicin against tumor neovasculature. Nanomedicine 8(1), 81-92 (2012).
68. Wang Z, Ho PC. A nanocapsular combinatorial sequential drug delivery system for antiangiogenesis and anticancer activities. Biomaterials 31(27), 7115-7123 (2010).
69. Patil Y, Sadhukha T, Ma L, Panyam J. Nanoparticle-mediated simultaneous and targeted delivery of paclitaxel and tariquidar overcomes tumor drug resistance. J. Control. Release 136(1), 21-29 (2009).
70. van Vlerken LE, Duan Z, Seiden MV, Amiji MM. Modulation of intracellular ceramide using polymeric nanoparticles to overcome multidrug resistance in cancer. Cancer Res. 67(10), 4843-4850 (2007). (Pubitemid 46910193)
71. van Vlerken LE, Duan Z, Little SR, Seiden MV, Amiji MM. Augmentation of therapeutic efficacy in drug-resistant tumor models using ceramide coadministration in temporal-controlled polymer-blend nanoparticle delivery systems. AAPS J 12(2), 171-180 (2010).
72. Patil YB, Swaminathan SK, Sadhukha T, Ma L, Panyam J. The use of nanoparticle-mediated targeted gene silencing and drug delivery to overcome tumor drug resistance. Biomaterials 31(2), 358-365 (2010).
73. Xiong XB, Lavasanifar A. Traceable multifunctional micellar nanocarriers for cancer-targeted co-delivery of MDR-1 siRNA and doxorubicin. ACS Nano 5(6), 5202-5213 (2011).
74. Lammers T, Kiessling F, Hennink WE, Storm G. Drug targeting to tumors: Principles, pitfalls and (pre-) clinical progress. J. Control. Release 161(2), 175-187 (2011).
75. Bae Y, Kataoka K. Intelligent polymeric micelles from functional poly(ethylene glycol)-poly(amino acid) block copolymers. Adv. Drug Deliver. Rev. 61(10), 768-784 (2009).
76. Lee HJ, Ponta A, Bae Y. Polymer nanoassemblies for cancer treatment and imaging. Ther. Deliv. 1(6), 803-817 (2010).